HRP20231315T1 - Imidazo[4,5-b]piridinski spojevi i njihovi farmaceutski pripravci radi liječenja upalnih poremećaja - Google Patents
Imidazo[4,5-b]piridinski spojevi i njihovi farmaceutski pripravci radi liječenja upalnih poremećaja Download PDFInfo
- Publication number
- HRP20231315T1 HRP20231315T1 HRP20231315TT HRP20231315T HRP20231315T1 HR P20231315 T1 HRP20231315 T1 HR P20231315T1 HR P20231315T T HRP20231315T T HR P20231315TT HR P20231315 T HRP20231315 T HR P20231315T HR P20231315 T1 HRP20231315 T1 HR P20231315T1
- Authority
- HR
- Croatia
- Prior art keywords
- independently selected
- alkyl
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims 2
- 238000011282 treatment Methods 0.000 title claims 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (15)
1. Spojevi sukladno Formuli I:
[image]
gdje
Cy je fenil ili 5-6-člani heteroaril koji sadrži jedan, dva ili tri N atoma;
L1 je jednostruka veza, -O-, -C(=O)-, -C(=O)O-, -S(O)2-, -NR6a-, -C(=O)NR6b-, -S(O)2NR6c- ili ‑C(=O)NR6dS(O)2-;
R1 je:
- H,
- C1-6 alkil, izborno supstituiran s jednim ili više neovisno odabranih od
∘ OH,
∘ halo,
∘ C1-4 alkoksi,
∘ -NR7aR7b,
∘ -C(=O)OH-,
∘ -C(=O)NR7cR7d,
∘ -C(=O)OC1-4 alkila, ili
∘ 4-8-članog monocikličnog heterocikloalkila koji sadrži jedan, dva ili tri heteroatoma neovisno odabrana od N, S i O;
- C3-7 cikloalkil, izborno supstituiran s jednim ili više od OH, C1-4 alkoksi, ili
- 4-9-člani monociklički ili spirobiciklički ili premošćeni ili kondenzirani biciklički heterocikloalkil koji sadrži jedan, dva ili tri heteroatoma neovisno odabrana od N, S i O; pri čemu je heterocikloalkil izborno supstituiran s jednom ili više neovisno odabranih R11 grupa;
svaki R11 je neovisno:
- OH,
- CN,
- halo,
- okso,
- -NR8aR8b,
- C3-7 cikloalkil,
- C1-4 alkil, izborno supstituiran s jednim ili više neovisno odabranih od halo, OH, C1-4 alkoksi, - NR9aR9b,
- C1-4 alkoksi, izborno supstituiran s jednim C1-4 alkoksi,
- 4-7-člani monocikličan heterocikloalkil koji sadrži jedan, dva ili tri heteroatoma neovisno odabrana od N, S i O,
- -C(=O)OC1-4alkil, ili
- -NR8cC(=O)OC1-4alkil;
R2 je
- halo,
- CN, ili
- C1-4 alkil;
indeks n je 0 ili 1;
L2 je O ili -NR4-,
R3 je
- C1-6 alkil, izborno supstituiran s jednim ili više neovisno odabranih od
∘ halo, ili
∘ C3-7 cikloalkila,
- Fenil supstituiran s jednom R5a grupom i jednom ili dvije neovisno odabrane R5b grupe,
- 6-člani heteroaril koji sadrži jedan ili dva N atoma, supstituiran s jednom R5a grupom i jednom ili dvije neovisno odabrane R5b grupe,
- 4-10-člani monociklični ili kondenzirani, premošćeni ili spiro biciklični heterocikloalkil koji sadrži jedan ili dva heteroatoma neovisno odabrana od N, S i O, izborno supstituiran s jednom, dvije ili tri grupe neovisno odabrane od R5a i R5b, ili
- 4-10-člani monociklični ili kondenzirani, premošćeni ili spiro biciklični cikloalkil, izborno supstituiran s jednom, dvije ili tri grupe neovisno odabrane od R5a i R5b;
R4 je
‑ H,
‑ C1-4 alkil, izborno supstituiran s jednim ili s više neovisno odabranih od OH ili C1-4 alkoksi, ili
‑ C3-7 cikloalkil;
R5a je -CN, -SO2-C1-4 alkil ili -CF3;
svaki R5b je neovisno odabran od halo, C1-4 alkila i C3-7 cikloalkila;
svaki R7a i R7b je neovisno odabran od
‑ H, i
‑ C1-4 alkila, izborno supstituiranog s jednim -NR10aR10b; i
svaki R6a, R6b, R6c, R6d, R7c, R7d, R8a, R8b, R8c, R9a, R9b, R10a i R10b je neovisno odabran od H i C1-4 alkila;
ili njegova farmaceutski prihvatljiva sol, ili solvat ili solvat njegove farmaceutski prihvatljive soli.
2. Spoj ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, gdje je L2 O.
3. Spoj ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, gdje je R3 odabran od:
[image]
4. Spoj ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, gdje je R3
[image]
5. Spoj ili njegova farmaceutski prihvatljiva sol sukladno bilo kojem od patentnih zahtjeva 1-4, gdje je R5a -CN, -SO2-C1-4 alkil ili -CF3.
6. Spoj ili njegova farmaceutski prihvatljiva sol sukladno bilo kojem od patentnih zahtjeva 1-4, gdje je R5b neovisno odabran od halo, C1-4 alkila i C3-7 cikloalkila.
7. Spoj ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, pri čemu je spoj u skladu s formulom IIIa, IIIb, IIIc ili IIId:
[image]
8. Spoj ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1 ili 7, gdje je L1 jednostruka veza ili -C(=O)-.
9. Spoj ili njegova farmaceutski prihvatljiva sol sukladno bilo kojem od patentnih zahtjeva 1-8, gdje je R1 4-9-člani monocikličan ili spirobicikličan ili premošćen ili kondenzirani biciklični heterocikloalkil koji sadrži jedan, dva ili tri heteroatoma neovisno odabrana od N, S i O; pri čemu je heterocikloalkil izborno supstituiran s jednom, dvije ili tri neovisno odabrane R11 grupe.
10. Spoj ili njegova farmaceutski prihvatljiva sol sukladno bilo kojem od patentnih zahtjeva 1-8, gdje je R1 azetidinil, oksetanil, pirolidinil, morfolinil, oktadeuteriomorfolin-4-il, tetrahidropiranil, piperazinil, dioksnil, od kojih je svaki supstituiran s jednom, dvije ili tri neovisno odabrane R11 grupe.
11. Spoj ili njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 9 ili 10, gdje je R11 C1-4 alkil, izborno supstituiran s jednim ili više neovisno odabranih od halo, OH, C1-4 alkoksi, ‑NR9aR9b, pri čemu je svaki R9a i R9b neovisan H ili C1-4 alkil.
12. Farmaceutsi pripravak koji sadrži farmaceutski prihvatljiv nosač i farmaceutski efektivnu količinu spojeva sukladno bilo kojem od patentnih zahtjeva 1-11.
13. Farmaceutski pripravak sukladno patentnom zahtjevu 12, koji sadrži dodatno terapijsko sredstvo.
14. Spoj ili njegova farmaceutski prihvatljiva sol, sukladno bilo kojem od patentnih zahtjeva 1-11 ili farmaceutski pripravak sukladno bilo kojem od patentnih zahtjeva 12-13, za upotrebu u medicini.
15. Spoj sukladno bilo kojem od patentnih zahtjeva 1-11 ili farmaceutski pripravak prema bilo kojem od zahtjeva 12-13, za upotrebu u liječenju ili profilaksi alergijskih bolesti, upalnih bolesti, metaboličkih bolesti, autoupalnih bolesti, autoimunih bolesti, proliferativnih bolesti, odbacivanje presatka, bolesti koje uključuju poremećaj izmjene hrskavice i/ili kongenitalne malformacije hrskavice.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1717260.2A GB201717260D0 (en) | 2017-10-20 | 2017-10-20 | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
EP18788711.2A EP3697784B9 (en) | 2017-10-20 | 2018-10-11 | Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
PCT/EP2018/077677 WO2019076716A1 (en) | 2017-10-20 | 2018-10-11 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231315T1 true HRP20231315T1 (hr) | 2024-02-16 |
Family
ID=60481889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231315TT HRP20231315T1 (hr) | 2017-10-20 | 2018-10-11 | Imidazo[4,5-b]piridinski spojevi i njihovi farmaceutski pripravci radi liječenja upalnih poremećaja |
Country Status (29)
Country | Link |
---|---|
US (2) | US11564923B2 (hr) |
EP (2) | EP3697784B9 (hr) |
JP (2) | JP7292271B2 (hr) |
KR (1) | KR20200074178A (hr) |
CN (2) | CN111225916B (hr) |
AR (1) | AR113784A1 (hr) |
AU (2) | AU2018350592B2 (hr) |
BR (1) | BR112020007541A2 (hr) |
CA (1) | CA3079449A1 (hr) |
CO (1) | CO2020005200A2 (hr) |
DK (1) | DK3697784T5 (hr) |
ES (1) | ES2967432T3 (hr) |
FI (1) | FI3697784T5 (hr) |
GB (1) | GB201717260D0 (hr) |
HR (1) | HRP20231315T1 (hr) |
HU (1) | HUE063998T2 (hr) |
IL (2) | IL302615A (hr) |
LT (1) | LT3697784T (hr) |
MA (1) | MA50391B1 (hr) |
MX (1) | MX2020003863A (hr) |
PH (1) | PH12020550230A1 (hr) |
PL (1) | PL3697784T3 (hr) |
PT (1) | PT3697784T (hr) |
RS (1) | RS64800B1 (hr) |
SG (1) | SG11202003516TA (hr) |
SI (1) | SI3697784T1 (hr) |
TW (1) | TWI805629B (hr) |
WO (1) | WO2019076716A1 (hr) |
ZA (1) | ZA202002166B (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
AU2020284742A1 (en) * | 2019-05-28 | 2022-02-03 | Mankind Pharma Ltd. | Novel compounds for inhibition of Janus Kinase 1 |
CA3225221A1 (en) | 2021-07-12 | 2023-01-19 | Galapagos Nv | Treatment of inflammatory diseases |
WO2023161327A1 (en) | 2022-02-24 | 2023-08-31 | Galapagos Nv | Compound for use in and methods of treatment of inflammatory diseases |
WO2023161326A1 (en) | 2022-02-24 | 2023-08-31 | Galapagos Nv | Compound for use in and methods of treatment of inflammatory diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
EP2809671B1 (en) * | 2012-01-30 | 2016-01-13 | Cephalon, Inc. | Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders |
GB201401086D0 (en) * | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2017012647A1 (en) | 2015-07-20 | 2017-01-26 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
AR105400A1 (es) * | 2015-08-04 | 2017-09-27 | Lilly Co Eli | Inhibidores de jak1 |
CN110300590A (zh) * | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
-
2017
- 2017-10-20 GB GBGB1717260.2A patent/GB201717260D0/en not_active Ceased
-
2018
- 2018-10-11 PT PT187887112T patent/PT3697784T/pt unknown
- 2018-10-11 SI SI201831002T patent/SI3697784T1/sl unknown
- 2018-10-11 EP EP18788711.2A patent/EP3697784B9/en active Active
- 2018-10-11 SG SG11202003516TA patent/SG11202003516TA/en unknown
- 2018-10-11 HR HRP20231315TT patent/HRP20231315T1/hr unknown
- 2018-10-11 DK DK18788711.2T patent/DK3697784T5/da active
- 2018-10-11 AU AU2018350592A patent/AU2018350592B2/en active Active
- 2018-10-11 PL PL18788711.2T patent/PL3697784T3/pl unknown
- 2018-10-11 CN CN201880067863.7A patent/CN111225916B/zh active Active
- 2018-10-11 FI FIEP18788711.2T patent/FI3697784T5/fi active
- 2018-10-11 WO PCT/EP2018/077677 patent/WO2019076716A1/en active Application Filing
- 2018-10-11 ES ES18788711T patent/ES2967432T3/es active Active
- 2018-10-11 LT LTEPPCT/EP2018/077677T patent/LT3697784T/lt unknown
- 2018-10-11 CN CN202311478101.5A patent/CN117534670A/zh active Pending
- 2018-10-11 MX MX2020003863A patent/MX2020003863A/es unknown
- 2018-10-11 BR BR112020007541-8A patent/BR112020007541A2/pt unknown
- 2018-10-11 JP JP2020521991A patent/JP7292271B2/ja active Active
- 2018-10-11 IL IL302615A patent/IL302615A/en unknown
- 2018-10-11 US US16/757,189 patent/US11564923B2/en active Active
- 2018-10-11 CA CA3079449A patent/CA3079449A1/en active Pending
- 2018-10-11 KR KR1020207014284A patent/KR20200074178A/ko not_active Application Discontinuation
- 2018-10-11 MA MA50391A patent/MA50391B1/fr unknown
- 2018-10-11 RS RS20231045A patent/RS64800B1/sr unknown
- 2018-10-11 EP EP23191626.3A patent/EP4265254A3/en active Pending
- 2018-10-11 HU HUE18788711A patent/HUE063998T2/hu unknown
- 2018-10-11 IL IL273943A patent/IL273943B2/en unknown
- 2018-10-19 AR ARP180103068A patent/AR113784A1/es unknown
- 2018-10-19 TW TW107136998A patent/TWI805629B/zh active
-
2020
- 2020-04-07 PH PH12020550230A patent/PH12020550230A1/en unknown
- 2020-04-27 CO CONC2020/0005200A patent/CO2020005200A2/es unknown
- 2020-05-04 ZA ZA2020/02166A patent/ZA202002166B/en unknown
-
2022
- 2022-12-27 US US18/146,698 patent/US20230310433A1/en active Pending
-
2023
- 2023-03-10 AU AU2023201522A patent/AU2023201522A1/en active Pending
- 2023-06-06 JP JP2023093474A patent/JP2023113834A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231315T1 (hr) | Imidazo[4,5-b]piridinski spojevi i njihovi farmaceutski pripravci radi liječenja upalnih poremećaja | |
HRP20171807T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija | |
HRP20210693T1 (hr) | Inhibitori beta-laktamaze | |
HRP20201641T1 (hr) | Novi spojevi i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja | |
HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
JP2015514808A5 (hr) | ||
HRP20171808T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija | |
HRP20210510T1 (hr) | 4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za liječenje hcv | |
HRP20221495T1 (hr) | Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita | |
HRP20200033T1 (hr) | 5-fenil-[1,2,4]triazolo[1,5-a]piridin-2-il karboksamidi kao jak inhibitori | |
HRP20180483T1 (hr) | Spoj kinolona | |
HRP20220885T1 (hr) | Spojevi imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaze | |
HRP20210038T1 (hr) | Pirolopirimidini za uporabu u infekciji virusom gripe | |
HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
HRP20161674T1 (hr) | 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE | |
MY174224A (en) | Hepatitis b virus surface antigen inhibitor | |
JP2014129360A5 (hr) | ||
HRP20211583T1 (hr) | Tienopiridini i benzotiofeni korisni kao irak4 inhibitori | |
HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
MY192029A (en) | 6, 7-dihydropyrazolo [1,5-()]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors | |
HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
SI2738156T1 (en) | TETRACYCLINE COMPOSITE SUBSTITUTED WITH 9-AMINOMETHYL | |
AR065719A1 (es) | Imidazo y triazolopirimidinas, un procedimiento para su preparacion y su uso en la elaboracion de un medicamento para el tratamiento de trastornos hematologicos. | |
SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
HRP20210783T1 (hr) | Derivati karboksamida |